Soft-Tissue and Osteosarcomas
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This study clinically evaluated the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class anti-TNFR2 antibody, as a novel immunotherapy for solid tumors. Preclinical modeling informed a first-in-human phase 1 dose-escalation trial in patients with solid cancers. BI-1808 was safe and well-tolerated, achieved full receptor occupancy, and induced tumor regression in two patients (non-small cell lung cancer and gastrointestinal sarcoma), with stable disease in 6 of 21 evaluable patients. Pharmacodynamic analyses confirmed dose-dependent regulatory T cell reduction, monocyte activation, and CD8+ T-cell activation, supporting further development of this mechanistically distinct immunotherapy.
10.1158/1078-0432.CCR-26-2049
Oct 05 – Oct 12, 2026
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The RINGSIDE phase II study evaluated varegacestat, an oral gamma-secretase inhibitor, in adults with desmoid tumors. This open-label, randomized, dose-finding trial assigned 42 participants 1:1:1 to 1.2-mg once-daily, 2-mg intermittent, or 4-mg intermittent dosing, with safety as the primary end point and tumor volume change at week 16 as the secondary end point. Median tumor volume reduction at week 16 was -51.91%, -15.25%, and -9.50%, respectively, with confirmed ORRs of 35.7%, 21.4%, and 21.4%; in the open-label extension, median best tumor volume change was -85.88% and ORR rose to 57.1%. Varegacestat produced clinically meaningful tumor reduction with a manageable safety profile, and the 1.2-mg once-daily dose was selected for phase III.
10.1200/JCO-26-00725
Sep 28 – Oct 05, 2026
Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
This first-in-human, single-arm, open-label, dose-escalation phase I trial evaluated the safety, tolerability, and preliminary antitumour efficacy of a novel carbon nanoparticle-Fe (II) complex (CNSI-Fe) administered via direct intratumoral injection in 19 patients with refractory solid tumors, using a 3+3 design across five dose levels (30-150 mg). The maximum tolerated dose was not reached, with only one dose-limiting toxicity event reported in the 90 mg cohort, and common adverse events included injection site pain (89.5%), hypertension (52.6%), elevated serum iron (47.4%), and anemia (47.4%). Pharmacokinetic analysis showed rapid iron absorption (peak time 0.15-0.41 h) and clearance (half-life 1.96-5.06 h), while preliminary efficacy demonstrated an overall response rate of 10.5% and a disease control rate of 84.2%. The authors concluded that CNSI-Fe has a favorable safety profile and promising antitumour activity, supporting further phase II investigation.
10.1038/s41392-026-02929-5
Sep 07 – Sep 14, 2026
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study analyzed circulating tumor DNA (ctDNA) in 313 plasma samples from 106 patients with localized soft tissue sarcoma treated with preoperative radiotherapy with or without pembrolizumab in the phase II randomized SU2C-SARC032 trial. Personalized ctDNA assays tracked a median of 46 somatic mutations, detecting baseline ctDNA in 85% of patients. Baseline ctDNA levels correlated with tumor size, grade 3 disease, and hypoxia/cell cycle gene expression, and ctDNA levels at multiple time points were strongly associated with disease-free and overall survival. The authors conclude that tumor-informed ctDNA profiling provides independent prognostic information and supports prospective ctDNA-guided interventional trials.
10.1200/JCO-26-00769
Aug 31 – Sep 07, 2026
Extended D3 Mesenterectomy in Small Bowel Cancer Treatment: Feasibility and Importance for Staging. First Results of a Prospective Clinical Trial.
WORLD J SURG · Q1 JOURNAL - RANK #70/312
This prospective clinical trial assessed the feasibility and staging implications of extended central (D3) mesenteric lymphadenectomy in 86 patients with small bowel cancer. Surgical techniques included preoperative 3D vascular mapping and standardized D3 resection of mesenteric tissue. D3 lymphadenectomy was achieved in 74 patients (86%), with a 7% reoperation rate (including 3% anastomotic leaks) and no 30-day mortality. Histopathology confirmed 60 small intestinal neuroendocrine tumors (siNETs) among 74 resected cases, with mesenteric lymph node metastases found in 62 patients (87%) and D3-volume metastases in 31 (44%). The authors conclude that D3 mesenterectomy is safe and radical, potentially improving staging accuracy and locoregional control, with subgroup analyses showing higher D3 positivity in proximal ileal siNETs (66%) compared to terminal ileal siNETs (29%).
10.1002/wjs.70550
Aug 17 – Aug 24, 2026
Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma.
TRENDS CANCER · Q1 JOURNAL - RANK #15/326TOP-TIER
This study evaluates a prospective clinical trial (SARC037) testing trabectedin combined with low-dose irinotecan in advanced Ewing sarcoma, focusing on downregulating the EWSR1::FLI1 fusion transcription factor. The early-phase trial employed histology-specific dosing and assessed clinical activity along with correlative biomarker changes. Key findings indicate the regimen demonstrated clinical activity and successfully downregulated EWSR1::FLI1 activity in this patient population. The authors conclude that this combination represents a promising therapeutic strategy for targeting transcription factor fusion-positive cancers.
10.1016/j.trecan.2026.07.010